1. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Issue 7 (July 2018) Authors: Russell, Richard J; Chachi, Latifa; FitzGerald, J Mark; Backer, Vibeke; Olivenstein, Ronald; Titlestad, Ingrid L; Ulrik, Charlotte Suppli; Harrison, Timothy; Singh, Dave; Chaudhuri, Rekha; Leaker, Brian; McGarvey, Lorcan; Siddiqui, Salman; Wang, Millie; Braddock, Martin; Nordenmark, Lars H; Cohen... Journal: Lancet Issue: Volume 6:Issue 7(2018) Page Start: 499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗